A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections

International Journal of Antimicrobial Agents

Volumn 12, Issue 2, 1999, Pages 121-127

  De Klerk, G J ^a,b   Van Steijn, J H M ^a   Lobatto, S ^a   Jaspers, C A J J ^b   Van Veldhuizen, W C J ^c   Hensing, C A J ^c   Bunnik, M C M ^d   Geraedts, W H ^d   Dofferhof, A S M ^e   Van Den Berg, J ^f   Melis, J H J M ^g   Hoepelman, A I M ^b  

^a Ziekenhuis Hilversum   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Diaconessenhuis Meppel   (Netherlands)

^d Maas Hospital Pantein   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f Ruwaard Van Putten Hospital   (Netherlands)

^g Kendle International   (Netherlands)

Author keywords

Ceftriaxone; Lower respiratory tract infections; Pneumonia; Standard therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CEFUROXIME; MACROLIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD; CHRONIC BRONCHITIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPUTUM; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BRONCHITIS; CEFTRIAXONE; CEPHALOSPORINS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 0033041813     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00037-0     Document Type: Article

References (24)

1. Capri S., Dellamano R. Cost-effectiveness in the hospital use of antibiotics: introductory considerations. J. Chemother. 5:1993;348-351.
2. Denton M., Morgan M.S., With R.R. Quality of prescibing of intravenous antibiotics in a district general hospital. Br. Med. J. 302:1991;327-328.
3. McCloskey R.V. Clinical and bacteriologic efficacy of ceftriaxone in the United States. Am. J. Med. 77(4c):1984;97-103.
4. Marklein G., Bell W.H., Bolcskei P., Borsch G., Czygan P., Grau R., Pilgrim R., Sodomann C.P., Tauchnitz C.H., Wendel H., Wertenbruch R. Ceftriaxone once a day in the treatment of pneumonia. Recent Adv. Chemother. Antimicrobial. Sect. 2:1991;2122-2123.
5. Patel H., Chen S., Parsonnet M., Hackman M.R., Brooks M.A., Konikoff J., Kaplan S.A. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20(5):1981;634-641.
6. Prichard J.G. Role of long-acting cephalosporins in ambulatory therapy. Clin. Ther. 10(6):1988;688-693.
7. McCabe R.E., Schlossberg D., Donowitz G.R., Scheld W.M., Zellner S.R., Lindenberg L.B., Armstrong J.H., Ein M.E. Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease. Clin. Ther. 11:1989;304-314.
8. Barradas P., Zamith M., Videira W., Cardosa T., Marques R.A., Avila R. Therapy of lower respiratory tract infections: a comparison of ceftriaxone and cefotaxime. Chemotherapy. 35(suppl. 2):1989;33-40.
9. Garber G.E., Auger P., Chan R.M.T., Conly J.M., Shafran S.D., Gerson M. A multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections. Diagn. Microbiol. Infect. Dis. 15:1992;85-88.
10. Hoepelman I.M., Rozenberg-Arska M., Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet. i:1988;1305-1309.
11. Mangi R.J., Peccerillo K.M., Ryan J., Berenson C., Greco T., Thornton G., Andriole V.T. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 15:1992;441-447.
12. Brown R. Once-daily ceftriaxone in the treatment of lower respiratory tract infections. Chemotherapy. 37(suppl.):1991;11-14.
13. Brown R.B., Sands M. One-gram intravenous ceftriaxone use in a large teaching hospital. Curr. Ther. Res. 46:1989;285-291.
14. Potgieter P.D., Linton D.M., Forder A.A., Plumb H. Ceftriaxone therapy in adults with severe lower respiratory tract infections. S. Afr. Med. J. 69:1986;495-497.
15. Segev S., Raz R., Rubenstein E., Shmuely H., Hassin D., Rosen N., Platau E., Ben Assuli S., Pitlik S. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur. J. Clin. Microbiol. Infect. Dis. 14:1995;851-855.
16. Poretz D.M., Woolard D., Eron L.J., Goldenberg R.I., Rising J., Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. Am. J. Med. 77(4c):1984;77-83.
17. Ramirez J.A., Srinath L., Ahkee S., Huang A., Raff M.J. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arc. Intern. Med. 155(12):1995;1273-1276.
18. Davis R., Bryson H.M. Ceftriaxone, a pharmacoeconomic evaluation of its use in the treatment of serious infections. PharmacoEconomics. 6(3):1994;249-269.
19. Niederman M.S., Bass J.B., Campbell G.D., Fein A.M., Grossman R.F., Mandell L.A., Marrie T.J., Sarosi G.A., Torres A., Yu V.L. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. Rev. Respir. Dis. 148(5):1993;1418-1426.
20. Campbell G.D., Niederman M.S., Brougton W.A. et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am. J. Resp. Crit. Care Med. 153:1996;1711-1725.
21. Lowenkron S.E., Niederman M.S. Definition and evaluation of the resolution of nosocomial pneumonia. Semin. Respir. Infect. 7:1992;271-281.
22. Anthonisen N.R., Manfreda J., Warren C.P.W., Hershfield E.S., Harding G.K.M., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Int. Med. 106:1987;196-204.
23. Meeker D.P., Longworth D.L. Community-acquired pneumonia: an update. Cleve. Clin. J. Med. 63(1):1996;16-30.
24. Grassi C., Mangiarotti P. International experiences with ceftriaxone in the treatment of lower respiratory tract infections. Chemiotherapia. 6:1987;364-373.